ALLMedicine™ Mycobacterium Abscessus Center

Mar 28th, 2023 - Mycobacterium abscessus is the most pathogenic species among the predominantly saprophytic fast-growing mycobacteria. This opportunistic human pathogen causes severe infections that are difficult to eradicate. Its ability to survive within the hos...

Mar 24th, 2023 - To present a patient with the first case of NTM (nontuberculous mycobacteria) infection of the larynx extending to cervical trachea, and the first case of subglottic stenosis associated with an NTM infection. Case report and review of the literatu...

Mar 23rd, 2023 - Because nontuberculous mycobacterial pulmonary disease is a considerable health burden, a simple and clinically applicable analytical protocol enabling the identification of subspecies and drug-resistant disease is required to determine the treatm...

Mar 23rd, 2023 - The total duration of subject participation in the study is approximately 5 months which includes a total duration of study treatment for approximately 3 months (84 days). Eligible participants will be randomized 1.5:1 to receive 3 months of treat...

Mar 15th, 2023 - Antimicrobial resistance and therapy-related adverse effects make Mycobacterium abscessus treatment challenging. Omadacycline is a novel, bioavailable aminomethylcycline with favourable in vitro activity against M. abscessus. To describe a case re...

Aug 17th, 2020 - Nontuberculous mycobacteria (NTM) represent over 190 species and subspecies, some of which can produce disease in humans of all ages and can affect both pulmonary and extrapulmonary sites. This guideline focuses on pulmonary disease in adults (wit...

Jul 9th, 2020 - Nontuberculous mycobacteria (NTM) represent over 190 species and subspecies, some of which can produce disease in humans of all ages and can affect both pulmonary and extrapulmonary sites. This guideline focuses on pulmonary disease in adults (wit...

Mar 23rd, 2023 - The total duration of subject participation in the study is approximately 5 months which includes a total duration of study treatment for approximately 3 months (84 days). Eligible participants will be randomized 1.5:1 to receive 3 months of treat...

Jan 10th, 2023 - A Screening period will begin up to 10 weeks prior to the Baseline visit for collection of the sputum sample, but the remainder of the assessments including Safety labs will be completed within 6 weeks of Baseline, to determine eligibility. Adult ...

Jan 9th, 2023 - Nontuberculous mycobacteria (NTM), consisting of more than 200 mycobacteria other than M. tuberculosis and M. leprae, is an environmental organism, which can be isolated from soil, dust and water. NTM can cause chronic diseases in human and the mo...

Sep 15th, 2022 - Mycobacterium abscessus (MABS) are a group of non-tuberculous mycobacteria (NTM) found in water and soil habitats that exhibit high levels of intrinsic multi-drug resistance. They are recognised opportunistic human pathogens capable of causing chr...

Sep 1st, 2022 - The single center, retrospective and prospective cohort study including the patients, aged 18 years and over, with acquired interferon-gamma autoantibody syndrome or chronic lung disease diagnosed with M. abscessus infection in the tertiary hospit...

Mar 8th, 2023 - Note that some links may require subscriptions. A cluster of Mycobacterium abscessus infections in four cardiac surgery patients at Brigham and Women's Hospital -- three of whom died -- was potentially attributable to a commercial water purifier, ...

May 11th, 2021 - NEW YORK (Reuters Health) - An analysis of whole genome data from cystic fibrosis patients reveals how multi-drug resistant pathogens evolve and suggests that Mycobacterium abscessus infection be treated promptly, contrary to current medical pract...

Oct 5th, 2020 - To the Editor: Immunosuppressed patients are at particular risk for disseminated mycobacterial infections. A locus minoris resistentiae offers less resistance to the infectious spread of these microorganisms.

Oct 1st, 2020 - The US Food and Drug Administration (FDA) is warning once again about the potential risk for nontuberculosis mycobacteria (NTM) infection during cardiothoracic surgery using cooler–heater devices. In a letter to healthcare providers, the FDA says ...

Jul 9th, 2019 - Case Report A 32-year-old woman presented to the dermatology clinic with a tender lump overlying the right maxilla of 6 weeks’ duration. The lesion developed acutely 1 to 2 months after the patient began using an at-home microdermabrasion device,.